{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-018042","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2025-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.370079+00:00","generated_at":"2026-05-18T09:20:27.810321+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nasdaq Panel grants Dermata Therapeutics exception until Aug 14, 2025 to meet minimum bid price rule","bullets":["Company received Nasdaq delisting notice on May 14, 2025 for failing minimum $1.00 bid price over 30 consecutive days.","Hearings Panel granted exception through August 14, 2025 to demonstrate compliance; suspension stayed during hearing process.","Dermata will seek shareholder approval for reverse stock split at July 15, 2025 annual meeting to regain compliance.","If compliance not achieved or other listing requirements unmet, common stock (DRMA) and warrants (DRMAW) may be delisted."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-018042","json":"https://secwatch.observer/filing/0001641172-25-018042.json","markdown":"https://secwatch.observer/filing/0001641172-25-018042.md","text":"https://secwatch.observer/filing/0001641172-25-018042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000164117225018042/0001641172-25-018042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000164117225018042/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:20:27.810321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f04015e929252e643f648e06d4f8be44fb4e019","claim":"Dermata Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"July 2, 2025, the Panel notified the Company that it has granted Company’s request for an exception until August 14, 2025, to demonstrate compliance with the Minimum Bid Price Requirement (the “Exception”). Pursuant to the Exception, the Company is required to provide the Panel with prompt notification of any significant events that occur, including any event that may call into question the Company’s ability to satisfy the terms of the Exception. The Company is actively pursuing measures to regain compliance with the Minimum Bid Price Requirement, including seeking shareholder approval for a r","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000164117225018042/0001641172-25-018042-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}